TNF-α downregulates vascular endothelial Flk-1 expression in human melanoma xenograft model

Chandrakala Menon, Malini Iyer, Indira Prabakaran, Robert J Canter, Shannon C. Lehr, Douglas L. Fraker

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

High-dose TNF with melphalan has significant antitumor activity in regional perfusion of the limbs and liver in human malignancies. TNF is believed to target tumor vasculature, but the precise molecular mechanism is unknown. The present study demonstrates that TNF downregulates the VEGF receptor, fetal liver kinase-1 (Flk-1), on tumor endothelium in a human melanoma xenograft model. NIH1286 human melanoma cells were transduced with a 720-bp fragment of the human VEGF121 gene to develop well-vascularized tumors that served as an amplified system for measuring Flk-1 expression changes. We injected 5 X 106 cells subcutaneously, each of two distinct single cell clones (NIH1286/3 and NIH1286/15), into athymic nude mice to produce tumors ∼10 mm in size. Each animal then received either BSA or TNF in BSA by tail vein. Tumors harvested at different time points post-TNF were analyzed for Flk-1 mRNA and protein expression. Data obtained showed that intravascular TNF downregulated Flk-1 expression in tumor endothelial cells. This effect could contribute to the antitumor activity of TNF known to target tumor vasculature.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Heart and Circulatory Physiology
Volume284
Issue number1 53-1
StatePublished - Jan 1 2003
Externally publishedYes

Fingerprint

Vascular Endothelial Growth Factor Receptor-2
Heterografts
Blood Vessels
Melanoma
Down-Regulation
Neoplasms
Nude Mice
Vascular Endothelial Growth Factor Receptor
Melphalan
Endothelium
Tail
Veins
Extremities
Endothelial Cells
Clone Cells
Perfusion
Messenger RNA
Liver

Keywords

  • Antiangiogenic therapy
  • Antitumor therapy
  • Antivascular therapy
  • Vascular endothelial growth factor receptor

ASJC Scopus subject areas

  • Physiology

Cite this

TNF-α downregulates vascular endothelial Flk-1 expression in human melanoma xenograft model. / Menon, Chandrakala; Iyer, Malini; Prabakaran, Indira; Canter, Robert J; Lehr, Shannon C.; Fraker, Douglas L.

In: American Journal of Physiology - Heart and Circulatory Physiology, Vol. 284, No. 1 53-1, 01.01.2003.

Research output: Contribution to journalArticle

Menon, Chandrakala ; Iyer, Malini ; Prabakaran, Indira ; Canter, Robert J ; Lehr, Shannon C. ; Fraker, Douglas L. / TNF-α downregulates vascular endothelial Flk-1 expression in human melanoma xenograft model. In: American Journal of Physiology - Heart and Circulatory Physiology. 2003 ; Vol. 284, No. 1 53-1.
@article{11a618648fb740ce832ac16f41ccba12,
title = "TNF-α downregulates vascular endothelial Flk-1 expression in human melanoma xenograft model",
abstract = "High-dose TNF with melphalan has significant antitumor activity in regional perfusion of the limbs and liver in human malignancies. TNF is believed to target tumor vasculature, but the precise molecular mechanism is unknown. The present study demonstrates that TNF downregulates the VEGF receptor, fetal liver kinase-1 (Flk-1), on tumor endothelium in a human melanoma xenograft model. NIH1286 human melanoma cells were transduced with a 720-bp fragment of the human VEGF121 gene to develop well-vascularized tumors that served as an amplified system for measuring Flk-1 expression changes. We injected 5 X 106 cells subcutaneously, each of two distinct single cell clones (NIH1286/3 and NIH1286/15), into athymic nude mice to produce tumors ∼10 mm in size. Each animal then received either BSA or TNF in BSA by tail vein. Tumors harvested at different time points post-TNF were analyzed for Flk-1 mRNA and protein expression. Data obtained showed that intravascular TNF downregulated Flk-1 expression in tumor endothelial cells. This effect could contribute to the antitumor activity of TNF known to target tumor vasculature.",
keywords = "Antiangiogenic therapy, Antitumor therapy, Antivascular therapy, Vascular endothelial growth factor receptor",
author = "Chandrakala Menon and Malini Iyer and Indira Prabakaran and Canter, {Robert J} and Lehr, {Shannon C.} and Fraker, {Douglas L.}",
year = "2003",
month = "1",
day = "1",
language = "English (US)",
volume = "284",
journal = "American Journal of Physiology - Renal Fluid and Electrolyte Physiology",
issn = "1931-857X",
publisher = "American Physiological Society",
number = "1 53-1",

}

TY - JOUR

T1 - TNF-α downregulates vascular endothelial Flk-1 expression in human melanoma xenograft model

AU - Menon, Chandrakala

AU - Iyer, Malini

AU - Prabakaran, Indira

AU - Canter, Robert J

AU - Lehr, Shannon C.

AU - Fraker, Douglas L.

PY - 2003/1/1

Y1 - 2003/1/1

N2 - High-dose TNF with melphalan has significant antitumor activity in regional perfusion of the limbs and liver in human malignancies. TNF is believed to target tumor vasculature, but the precise molecular mechanism is unknown. The present study demonstrates that TNF downregulates the VEGF receptor, fetal liver kinase-1 (Flk-1), on tumor endothelium in a human melanoma xenograft model. NIH1286 human melanoma cells were transduced with a 720-bp fragment of the human VEGF121 gene to develop well-vascularized tumors that served as an amplified system for measuring Flk-1 expression changes. We injected 5 X 106 cells subcutaneously, each of two distinct single cell clones (NIH1286/3 and NIH1286/15), into athymic nude mice to produce tumors ∼10 mm in size. Each animal then received either BSA or TNF in BSA by tail vein. Tumors harvested at different time points post-TNF were analyzed for Flk-1 mRNA and protein expression. Data obtained showed that intravascular TNF downregulated Flk-1 expression in tumor endothelial cells. This effect could contribute to the antitumor activity of TNF known to target tumor vasculature.

AB - High-dose TNF with melphalan has significant antitumor activity in regional perfusion of the limbs and liver in human malignancies. TNF is believed to target tumor vasculature, but the precise molecular mechanism is unknown. The present study demonstrates that TNF downregulates the VEGF receptor, fetal liver kinase-1 (Flk-1), on tumor endothelium in a human melanoma xenograft model. NIH1286 human melanoma cells were transduced with a 720-bp fragment of the human VEGF121 gene to develop well-vascularized tumors that served as an amplified system for measuring Flk-1 expression changes. We injected 5 X 106 cells subcutaneously, each of two distinct single cell clones (NIH1286/3 and NIH1286/15), into athymic nude mice to produce tumors ∼10 mm in size. Each animal then received either BSA or TNF in BSA by tail vein. Tumors harvested at different time points post-TNF were analyzed for Flk-1 mRNA and protein expression. Data obtained showed that intravascular TNF downregulated Flk-1 expression in tumor endothelial cells. This effect could contribute to the antitumor activity of TNF known to target tumor vasculature.

KW - Antiangiogenic therapy

KW - Antitumor therapy

KW - Antivascular therapy

KW - Vascular endothelial growth factor receptor

UR - http://www.scopus.com/inward/record.url?scp=0037235099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037235099&partnerID=8YFLogxK

M3 - Article

VL - 284

JO - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

JF - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

SN - 1931-857X

IS - 1 53-1

ER -